PMID- 18365787
OWN - NLM
STAT- MEDLINE
DCOM- 20080918
LR  - 20131121
IS  - 1139-9287 (Print)
IS  - 1139-9287 (Linking)
VI  - 36
IP  - 2
DP  - 2008 Mar-Apr
TI  - [Long-acting injectable risperidone in treatment resistant borderline personality 
      disorder. A small series report].
PG  - 70-4
AB  - INTRODUCTION: Borderline personality disorder (BPD) is usually treated with a 
      combination of antipsychotic and anticonvulsant drugs although only limited 
      efficacy is obtained in many patients. A major problem in the treatment of BPD is 
      the lack of compliance derived form the pathological impulsivity of BPD patients. 
      METHODS: Twelve severe BPD patients refractory to previous treatment with drug 
      combinations for three months were treated with intramuscular long-acting 
      risperidone for a six-month period. Clinical changes were rated with the Clinical 
      Global Impression (CGI), the Brief Psychiatric Rating Scale, anxiety and 
      aggression scales. Functional improvement was evaluated with the Global 
      Assessment of Functioning (GAF). RESULTS: Six-month treatment with IM risperidone 
      was associated with significant improvement of CGI (t: 5.7 - 4.0; p<0.01) and of 
      GAF (t: -4.5; gl: 10; p<0.01). Clinical improvement was robust after the first 
      month of treatment. No relevant extrapiramidal side effects were reported with 
      the exception of mild psychomotor slowing which requires dose adjustments in four 
      patients. CONCLUSIONS: Treatment with i.m. long acting risperidone during six 
      months was associated with significant clinical and functional improvement and 
      excellent tolerability in a group of BPD patients refractory to previous 
      treatment. The results indicate that the effect of IM risperidone in BPD should 
      be further investigated in large placebo-controlled trials.
FAU - Diaz-Marsa, M
AU  - Diaz-Marsa M
AD  - Psychiatry Department, Hospital Clinico San Carlos, Madrid, Spain. 
      mdiazm.hcsc@salud.madrid.org
FAU - Galian, M
AU  - Galian M
FAU - Montes, A
AU  - Montes A
FAU - Fernandez, R
AU  - Fernandez R
FAU - Arza, R
AU  - Arza R
FAU - Lopez-Ibor, Jj
AU  - Lopez-Ibor J
FAU - Carrasco, Jl
AU  - Carrasco J
LA  - spa
PT  - English Abstract
PT  - Journal Article
TT  - Risperidona intramuscular de accion prolongada en el trastorno limite de la 
      personalidad resistente al tratamiento.Un estudio piloto.
PL  - Spain
TA  - Actas Esp Psiquiatr
JT  - Actas espanolas de psiquiatria
JID - 100886502
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - L6UH7ZF8HC (Risperidone)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antipsychotic Agents/*therapeutic use
MH  - Borderline Personality Disorder/*drug therapy
MH  - Delayed-Action Preparations/therapeutic use
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Male
MH  - Risperidone/*therapeutic use
MH  - Severity of Illness Index
EDAT- 2008/03/28 09:00
MHDA- 2008/09/19 09:00
CRDT- 2008/03/28 09:00
PHST- 2008/03/28 09:00 [pubmed]
PHST- 2008/09/19 09:00 [medline]
PHST- 2008/03/28 09:00 [entrez]
AID - 20081111212 [pii]
PST - ppublish
SO  - Actas Esp Psiquiatr. 2008 Mar-Apr;36(2):70-4.